LianBio

LIANY · OTC · SIC 2834: Pharmaceutical Preparations
50
SEC Filings

Business Summary

PART I Overview We are a clinical stage biopharmaceutical company dedicated to bringing innovative medicines to patients with unmet medical needs in Asia. Our initial focus is to in-license assets for development and commercialization in Greater China and other Asian markets. We have assembled a pipeline of eight therapeutic candidates across cardiovascular, oncology, ophthalmology, and inflammatory disease indications, each with its own distinct value proposition and the potential to drive new ...

Next Earnings

Q2 FY2026 — expected 2026-08-13

Key Facts from Earnings Calls

TypeSubjectDetailQuarter
topic_mentionLIANYdiscussed_in_filing Cybersecurity
topic_mentionLIANYdiscussed_in_filing Trusted Computing
topic_mentionLIANYdiscussed_in_filing Blockchain & Crypto
topic_mentionLIANYdiscussed_in_filing Regulation
topic_mentionLIANYdiscussed_in_filing Healthcare & Bio
topic_mentionLIANYdiscussed_in_filing Sovereign & Government
topic_mentionLIANYdiscussed_in_filing Cybersecurity
topic_mentionLIANYdiscussed_in_filing Trusted Computing
topic_mentionLIANYdiscussed_in_filing Blockchain & Crypto
topic_mentionLIANYdiscussed_in_filing Regulation
topic_mentionLIANYdiscussed_in_filing Healthcare & Bio
topic_mentionLIANYdiscussed_in_filing Sovereign & Government
topic_mentionLIANYdiscussed_in_filing Cybersecurity
topic_mentionLIANYdiscussed_in_filing Trusted Computing
topic_mentionLIANYdiscussed_in_filing Blockchain & Crypto
topic_mentionLIANYdiscussed_in_filing Regulation
topic_mentionLIANYdiscussed_in_filing Healthcare & Bio
topic_mentionLIANYdiscussed_in_filing Sovereign & Government
topic_mentionLIANYdiscussed_in_filing Cybersecurity
topic_mentionLIANYdiscussed_in_filing Trusted Computing

Annual Reports (10-K)

FiledPeriodAccessionSourceFull Text
2023-03-282022-12-310001831283-23-000041EDGAR162K words
2022-03-312021-12-310001831283-22-000014EDGAR—

Quarterly Reports (10-Q)

FiledPeriodAccessionSourceFull Text
2023-11-132023-09-300001831283-23-000126EDGAR26K words
2023-08-142023-06-300001831283-23-000110EDGAR—
2023-05-112023-03-310001831283-23-000081EDGAR—
2022-11-102022-09-300001831283-22-000075EDGAR—
2022-08-112022-06-300001831283-22-000061EDGAR—
2022-05-122022-03-310001831283-22-000042EDGAR—
2021-12-092021-09-300001193125-21-352813EDGAR—

Recent Current Reports (8-K)

FiledAccessionSourceFull Text
2024-02-130001831283-24-000004EDGAR2K words
2023-12-260001831283-23-000145EDGAR—
2023-12-200001831283-23-000141EDGAR—
2023-12-190001831283-23-000137EDGAR—
2023-12-060001831283-23-000133EDGAR—
2023-12-010001831283-23-000129EDGAR—
2023-11-130001831283-23-000124EDGAR—
2023-10-300001831283-23-000117EDGAR—
2023-08-140001831283-23-000107EDGAR—
2023-06-230001831283-23-000092EDGAR—

50 total filings indexed. 31 additional filings (S-1, DEF 14A, etc.) View all (JSON) · SEC EDGAR

Sector Peers

SXTP — 60 DEGREES PHARMACEUTICALS, INC. ABT — ABBOTT LABORATORIES ABEO — ABEONA THERAPEUTICS INC. ABVC — ABVC BIOPHARMA, INC. ACAD — ACADIA PHARMACEUTICALS INC ACTU — ACTUATE THERAPEUTICS, INC. ADCT — ADC Therapeutics SA ADIL — ADIAL PHARMACEUTICALS, INC.

Company Identity

CIK0001831283
TickerLIANY
ExchangeOTC
SIC2834: Pharmaceutical Preparations
IncorporatedE9

Get More Data

This is the free public profile. For structured JSON with full provenance chain, use the API:

JSON Profile Stock Quote AI Readiness Report
Origin Provenance
page leaf: b332c2056080ae3a6f411a6885a5f3a6857ef14fba78052db54447ca51ab41bf
parent: 482be062597f97ec4b1328c2f19f91607bcab01cca75e26d4aa78fc3d0afb04f
content hash: 897d6fcf8ef4fff12f9c40b5e09a7ebc352d646e06587541ac5df7f544edb711
signed: 2026-04-13T04:46:02.139Z
sources: 9 verified data leaves
chain: SEC.gov PEM → origin.rootz.global extraction → this page
verify: sha256(content_hash + parent + timestamp) = leaf